Total Payments
$1.2M
2024 Payments
$145,319
Companies
22
Transactions
1,025
Medicare Patients
1,072
Medicare Billing
$122,297
Payment Breakdown by Category
Other$666,231 (54.6%)
Consulting$385,333 (31.6%)
Travel$121,296 (9.9%)
Research$26,917 (2.2%)
Food & Beverage$21,436 (1.8%)
Education$14.23 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $562,681 | 185 | 46.1% |
| Consulting Fee | $385,333 | 94 | 31.6% |
| Travel and Lodging | $121,296 | 318 | 9.9% |
| Honoraria | $53,454 | 24 | 4.4% |
| Unspecified | $26,917 | 10 | 2.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $26,510 | 10 | 2.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $23,586 | 8 | 1.9% |
| Food and Beverage | $21,436 | 374 | 1.8% |
| Education | $14.23 | 2 | 0.0% |
Payments by Type
General
$1.2M
1,015 transactions
Research
$26,917
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $358,308 | 377 | $0 (2024) |
| Gilead Sciences, Inc. | $312,650 | 333 | $0 (2024) |
| Intercept Pharmaceuticals, Inc. | $194,334 | 101 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $126,603 | 46 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $65,524 | 54 | $0 (2017) |
| Shionogi Inc | $44,244 | 27 | $0 (2020) |
| Bausch Health US, LLC | $23,875 | 6 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $23,427 | 16 | $0 (2023) |
| Madrigal Pharmaceuticals | $18,615 | 17 | $0 (2024) |
| Mirum Pharmaceuticals, Inc. | $18,202 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $145,319 | 75 | Intercept Pharmaceuticals, Inc. ($76,796) |
| 2023 | $86,110 | 69 | Mallinckrodt Hospital Products Inc. ($33,793) |
| 2022 | $141,750 | 101 | Gilead Sciences, Inc. ($38,555) |
| 2021 | $116,917 | 60 | Gilead Sciences, Inc. ($40,203) |
| 2020 | $128,417 | 84 | AbbVie Inc. ($32,953) |
| 2019 | $195,844 | 187 | AbbVie, Inc. ($57,747) |
| 2018 | $153,055 | 186 | AbbVie, Inc. ($100,571) |
| 2017 | $253,815 | 263 | AbbVie, Inc. ($111,207) |
All Payment Transactions
1,025 individual payment records from CMS Open Payments — Page 1 of 41
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,100.00 | General |
| Category: CRITICAL CARE | ||||||
| 12/07/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,763.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/07/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,410.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.41 | General |
| 11/29/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,960.00 | General |
| Category: CRITICAL CARE | ||||||
| 11/21/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $147.56 | General |
| Category: CRITICAL CARE | ||||||
| 10/30/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 10/30/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $130.14 | General |
| Category: LIVER DISEASE | ||||||
| 10/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $3.92 | General |
| 10/24/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Food and Beverage | In-kind items and services | $100.38 | General |
| Category: Alagille syndrome | ||||||
| 10/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $6.06 | General |
| 10/11/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Consulting Fee | Cash or cash equivalent | $66,803.15 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 10/11/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,790.00 | General |
| Category: HBV | ||||||
| 10/11/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 10/11/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Honoraria | Cash or cash equivalent | $1,083.98 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 10/10/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Food and Beverage | In-kind items and services | $143.92 | General |
| Category: HBV | ||||||
| 10/10/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Travel and Lodging | In-kind items and services | $35.24 | General |
| Category: HBV | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,935.00 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $441.57 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $254.00 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $226.86 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $199.10 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $186.86 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $94.62 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $80.91 | General |
| Category: LIVER DISEASE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RIFAXIMIN SOLUBLE DISPERSION SSD TABLETS PLUS LACTULOSE AND RIFAXIMIN EXTENDED INTESTINAL RELEASE EIR TABLETS PLUS LACTULOSE FOR THE TREATMENT OF OVERT HEPATIC ENCEPHALOPATHY OHE. | Bausch Health US, LLC | $23,875 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 199 | 216 | $121,855 | $19,572 |
| 2022 | 6 | 234 | 255 | $89,595 | $22,759 |
| 2021 | 9 | 301 | 425 | $131,920 | $38,815 |
| 2020 | 11 | 338 | 478 | $153,740 | $41,152 |
Total Patients
1,072
Total Services
1,374
Medicare Billing
$122,297
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 83 | 96 | $40,800 | $7,851 | 19.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 44 | 48 | $26,400 | $6,112 | 23.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 31 | 31 | $16,275 | $3,176 | 19.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 12 | $5,100 | $1,184 | 23.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 12 | 12 | $24,780 | $1,087 | 4.4% |
| 91200 | Measurement of liver stiffness | Facility | 2023 | 17 | 17 | $8,500 | $160.82 | 1.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 78 | 83 | $30,515 | $9,014 | 29.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 51 | 51 | $26,775 | $6,958 | 26.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 28 | 31 | $15,530 | $4,511 | 29.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 25 | $6,130 | $1,602 | 26.1% |
| 91200 | Measurement of liver stiffness | Office | 2022 | 18 | 18 | $9,000 | $533.28 | 5.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 47 | 47 | $1,645 | $139.50 | 8.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 100 | 109 | $37,060 | $11,989 | 32.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 29 | 110 | $25,300 | $7,352 | 29.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 34 | 36 | $16,380 | $5,845 | 35.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 18 | 49 | $16,170 | $4,702 | 29.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 27 | 27 | $14,175 | $4,191 | 29.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 16 | 16 | $10,400 | $3,193 | 30.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 14 | 14 | $3,220 | $975.93 | 30.3% |
| 91200 | Measuring the stiffness in the liver via elastography | Office | 2021 | 15 | 15 | $7,500 | $421.98 | 5.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 48 | 49 | $1,715 | $144.00 | 8.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 37 | 101 | $33,330 | $9,748 | 29.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 84 | 94 | $31,960 | $8,536 | 26.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 30 | 89 | $20,470 | $5,815 | 28.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 23 | 24 | $15,600 | $4,414 | 28.3% |
About Dr. Robert Brown, MD
Dr. Robert Brown, MD is a Hepatology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1396782629.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Brown, MD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $145,319 received in 2024. These payments were reported across 1,025 transactions from 22 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($562,681).
As a Medicare-enrolled provider, Brown has provided services to 1,072 Medicare beneficiaries, totaling 1,374 services with total Medicare billing of $122,297. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Hepatology
- Location New York, NY
- Active Since 06/02/2006
- Last Updated 09/26/2013
- Taxonomy Code 207RI0008X
- Entity Type Individual
- NPI Number 1396782629
Products in Payments
- Epclusa (Drug) $165,995
- OCALIVA (Drug) $162,483
- Mavyret (Drug) $150,114
- Vemlidy (Drug) $71,900
- Viekira (Drug) $71,013
- TERLIVAZ (Drug) $67,429
- MAVYRET (Drug) $66,612
- Mulpleta (Drug) $36,792
- XIFAXAN (Drug) $32,218
- ZEPATIER (Drug) $21,114
- LIVTENCITY (Drug) $19,387
- REZDIFFRA (Drug) $18,615
- Doptelet (Drug) $12,085
- OCA (Drug) $9,177
- Vosevi (Drug) $7,857
- Livmarli (Drug) $7,033
- Bylvay (Drug) $4,550
- IMFINZI (Biological) $2,281
- BENLYSTA (Biological) $948.71
- OPDIVO (Biological) $70.76
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hepatology Doctors in New York
Douglas Dieterich, Md, MD
Hepatology — Payments: $1.1M
Hepatology $1.1M
Meena Bansal, Md, MD
Hepatology — Payments: $174,483
Hepatology $174,483
Tatyana Kushner
Hepatology — Payments: $136,277
Hepatology $136,277
Mr. Giuseppe Cullaro, M.d, M.D
Hepatology — Payments: $50,390
Hepatology $50,390
Augusto Villanueva Rodriguez, Md, Phd, MD, PHD
Hepatology — Payments: $31,912
Hepatology $31,912
Dr. Ritu Agarwal, M.d, M.D
Hepatology — Payments: $5,707
Hepatology $5,707